Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NF-kappaB Decoy in Atopic Dermatitis
NCT00125333Phase 2Completed
- Sponsor
- Anesiva
- Start
- Mar 2005
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of eblasakimab in atopic dermatitis (AD) (4 arms), sponsored by Anesiva. Primary endpoint: Safety and tolerability of twice-daily topical application. Started Mar 2005; status: completed.
02
Drugs
eblasakimab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT00125333.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00125333.